Risk of progression of Barrett's esophagus in patients with cirrhosis

被引:3
|
作者
Apfel, Tehilla [1 ]
Lopez, Rocio [1 ]
Sanaka, Madhusudhan R. [1 ]
Thota, Prashanthi N. [1 ]
机构
[1] Cleveland Clin Fdn, Dept Gen Internal Med, Cleveland, OH 44195 USA
关键词
Liver cirrhosis; Barrett's esophagus; Dysplasia; Esophageal neoplasm; Progression; NONALCOHOLIC FATTY LIVER; HIGH-GRADE DYSPLASIA; GASTROESOPHAGEAL-REFLUX; METABOLIC SYNDROME; ADENOCARCINOMA; VARICES; METAANALYSIS; ADIPOKINES; DISEASE;
D O I
10.3748/wjg.v23.i18.3287
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM To study Barrett's esophagus (BE) in cirrhosis and assess progression to esophageal adenocarcinoma (EAC) compared to non-cirrhotic BE controls. METHODS Cirrhotic patients who were found to have endoscopic evidence of BE confirmed by the presence of intestinal metaplasia on histology from 1/1/2000 to 12/1/2015 at Cleveland Clinic were included. Cirrhotic patients were matched 1: 4 to BE controls without cirrhosis. Age, gender, race, BE length, hiatal hernia size, Child-Pugh (CP) class and histological findings were recorded. Cases and controls without high-grade dysplasia (HGD)/EAC and who had follow-up endoscopies were studied for incidence of dysplasia/EAC and to assess progression rates. Univariable conditional logistic regression was done to assess differences in baseline characteristics between the two groups. RESULTS A total of 57 patients with cirrhosis and BE were matched with 228 controls (BE without cirrhosis). The prevalence of dysplasia in cirrhosis and controls were similar with 8.8% vs 12% with low grade dysplasia (LGD) and 12.3 % vs 19.7% with HGD or EAC (P = 0.1). In the incidence cohort of 44 patients with median follow-up time of 2.7 years [interquartile range 1.0, 4.8], there were 7 cases of LGD, 2 cases of HGD, and 2 cases of EAC. There were no differences in incidence rates of HGD/ EAC in nondysplastic BE between cirrhotic cases and noncirrhotic controls (1.4 vs 1.1 per 100 person-years, P = 0.8). In LGD, cirrhotic patients were found to have higher rates of progression to HGD/EAC compared to control group though this did not reach statistical significance (13.7 vs 8.1 per 100 person-years, P = 0.51). A significant association was found between a higher CP class and neoplastic progression of BE in cirrhotic patients (HR = 7.9, 95% CI: 2.0-30.9, P = 0.003). CONCLUSION Cirrhotics with worsening liver function are at increased risk of progression of BE. More frequent endoscopic surveillance might be warranted in such patients.
引用
收藏
页码:3287 / 3294
页数:8
相关论文
共 50 条
  • [41] Risk Factors for Progression of Barrett's Esophagus With Low-Grade Dysplasia
    Tavakkoli, Anna
    Appelman, Henry D.
    Beer, David G.
    Madiyal, Chaitra
    Khodadost, Maryam
    Nofz, Kimberly
    Metko, Val
    Wang, Thomas
    Rubenstein, Joel H.
    GASTROENTEROLOGY, 2016, 150 (04) : S177 - S177
  • [42] Hypertension Is Associated with Reduced Risk of Progression to Dysplasia/Cancer in Barrett's Esophagus
    Thota, Prashanthi
    Lee, Hyun Ju
    Gohel, Tushar
    Oldenburgh, Mary
    Dai, Jie
    Lopez, Rocio
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S16 - S16
  • [43] Dysplastic Barrett's Esophagus in Cirrhosis: A Treatment Dilemma
    Raftopoulos, S. C.
    Efthymiou, M.
    May, G.
    Marcon, N.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 (09): : 1724 - 1726
  • [44] REDUCED ESOPHAGEAL CONTRACTILITY IS A RISK FACTOR FOR DYSPLASIA PROGRESSION IN BARRETT'S ESOPHAGUS
    Yadlapati, Rena H.
    Van de Voorde, Zoe
    Triggs, Joseph
    Quader, Farhan
    Eluri, Swathi
    Bhatia, Shweta
    Kaizer, Alexander
    Pandolfino, John E.
    Komanduri, Sri
    Gyawali, C. Prakash
    Shaheen, Nicholas J.
    Menard-Katcher, Paul
    Wani, Sachin B.
    GASTROENTEROLOGY, 2019, 156 (06) : S292 - S292
  • [45] Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia
    Gappa, Birgit
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2018, 56 (08): : 878 - +
  • [46] Barrett's Esophagus Length is an Independent Risk Factor for Progression to Esophageal Adenocarcinoma
    Tofani, Christina
    Gandhi, Kunjal
    Spataro, Joseph
    Yoo, Joseph
    Murphy, Megan
    Mohan, Neena
    Daitch, Zachary
    Shah, Apeksha
    Janowski, Raymond
    Dabbish, Noreen
    Keith, Scott
    Kastenberg, David
    Coben, Robert M.
    Cohen, Sidney
    Infantolino, Anthony
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S172 - S173
  • [47] Regular NSAID use might reduce the risk of progression of Barrett's esophagus
    Caroline Barranco
    Nature Clinical Practice Gastroenterology & Hepatology, 2006, 3 (2): : 62 - 62
  • [48] A microRNA Signature Identifies Patients at Risk of Barrett Esophagus Progression to Dysplasia and Cancer
    James Saller
    Kun Jiang
    Yin Xiong
    Sean J. Yoder
    Kevin Neill
    Jose M. Pimiento
    Luis Pena
    F. Scott Corbett
    Anthony Magliocco
    Domenico Coppola
    Digestive Diseases and Sciences, 2022, 67 : 516 - 523
  • [49] A microRNA Signature Identifies Patients at Risk of Barrett Esophagus Progression to Dysplasia and Cancer
    Saller, James
    Jiang, Kun
    Xiong, Yin
    Yoder, Sean J.
    Neill, Kevin
    Pimiento, Jose M.
    Pena, Luis
    Corbett, F. Scott
    Magliocco, Anthony
    Coppola, Domenico
    DIGESTIVE DISEASES AND SCIENCES, 2022, 67 (02) : 516 - 523
  • [50] Barrett esophagus -: Risk factors for progression to dysplasia and adenocarcinoma
    Öberg, S
    Wenner, J
    Johansson, J
    Walther, B
    Willén, R
    ANNALS OF SURGERY, 2005, 242 (01) : 49 - 54